Please login to the form below

Not currently logged in
Email:
Password:

Stem cell

This page shows the latest Stem cell news and features for those working in and with pharma, biotech and healthcare.

NICE recommends Astellas’ Xospata for NHS use

NICE recommends Astellas’ Xospata for NHS use

drug after a stem cell transplant.

Latest news

More from news
Approximately 7 fully matching, plus 218 partially matching documents found.

Latest Intelligence

  • Gut instincts lead Takeda to GI pipeline success Gut instincts lead Takeda to GI pipeline success

    Takeda’s Asit Parikh talks about a game changer for IBD patients and the company’s long-term strategy for gene and cell therapy. ... It is targeted for market approval in 2022. The promise continues with a phase 3 trial deploying Entyvio as a support

  • Novo Nordisk awakens its ‘Sleeping Beauty’ Novo Nordisk awakens its ‘Sleeping Beauty’

    Science at full speed. “Gene therapy is a revolution with the long-term potential of getting into the cell to remove the faulty DNA that would really cure patients for life,” ... We also have a stem cell platform, gene editing, an exquisite oral

  • Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019 Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019

    Its only immediate competition will be donor stem cell transplants, which carry significant patient risks.

  • Bluebird: on a mission to ‘recode’ the DNA of healthcare Bluebird: on a mission to ‘recode’ the DNA of healthcare

    Much of this pricing is based on direct comparisons with the costs of lifelong blood transfusions and haematopoietic stem cell (HSC) transplantation. ... won’t need the high-cost allogeneic haematopoietic stem cell transplantation which is currently

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    1. Zolgensma – the $4m per patient gene therapy. The first CAR-T cell therapies, Novartis’ Kymriah and Gilead/Kite’s Yescarta, were launched in Europe in 2018, while Spark’s gene ... The analysts predict the drug will be priced at around $550,

More from intelligence
Approximately 0 fully matching, plus 32 partially matching documents found.

Latest appointments

  • Industry appointments Industry appointments

    Rogerio Vivaldi leaves Bioverativ buyout to head up Sigilon. US-based biotech Sigilon aiming to deliver stem cell therapies for diabetes is getting a new leader. ... In the longer term, Hassan will lead research activities with the aim to expand

  • Weekly industry appointments Weekly industry appointments

    There, he is medicines development leader for adenosine deaminase deficiency (ADA-SCID) gene therapy Strimvelis – the first alternative medicine to stem cell transplant for the disease that’s bagged a regulatory ... be a global leader in the

  • Porterhouse Medical promotes Emma Conran Porterhouse Medical promotes Emma Conran

    Conran has served in medical writing positions at Porterhouse Medical since 2014 and prior to that she was a translational stem cell biology lecturer at King’s College London.

  • apceth Biopharma appoints Dusan Kosijer as CFO apceth Biopharma appoints Dusan Kosijer as CFO

    successful track record as one of the leading CDMOs for complex cell and gene therapy products. ... Moreover, Dusan’s experience will strongly promote our dynamic innovative strategy behind apceth’s unique proprietary pipeline of genetically modified

  • Dr Jay Stout moves from Merck to SanBio Dr Jay Stout moves from Merck to SanBio

    In this role, he is responsible for all production-related operations, including clinical cell preparation, final quality assurance and process development. ... He is perhaps the individual with the greatest experience in the world in manufacturing

More from appointments
Approximately 1 fully matching, plus 10 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 2 fully matching, plus 10 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

Virtual Hackathon on Healthcare Innovation: a Customer Story
How participants from 9 different countries in the APAC region were brought together to participate in a pharmaceutical company-wide 3-day virtual "hackathon," with spectacular results....
OPEN Health at the World Orphan Drug Conference USA
Our Director of Rare Disease, Gavin Jones looks forward to his conversation with Emily Crossle & Betsy Bogard at #WODCUSA2020 !...
Can involving patients in design transform the clinical trial experience?
While the research space is a heavily regulated environment and there are rules that we must abide by, this doesn’t mean clinical study materials have to be ‘boring’ or the...

Infographics